HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Panobinostat, a pan-HDAC inhibitor, produced an ORR of 67% in participants with advanced CTCL (n/N = 6/10) when administered as oral monotherapy [78]; however, in a larger phase 2 cohort of 139 participants with refractory CTCL, the ORR was 17% [77].